Starpharma
Contact Search
Home
Company
About Starpharma
Dendrimer Technology
DEP® Drug Delivery Platform
Leadership
Our Capabilities
Research Publications
ESG
Pipeline & Products
DEP® Pipeline
DEP® SN38
DEP® cabazitaxel
DEP® docetaxel
DEP® radiopharmaceuticals
DEP® antibody-drug conjugates
Anti-infective Products
Partnerships
Partnerships
Investors
Investor Information
ASX Announcements
Financial Reports
Corporate Governance
News
Email Alerts
Annual General Meeting 2024
People & Culture
Our People & Culture
Careers
  1. Investors
  2. Corporate Governance

Corporate Governance

  • Corporate Governance Statement 2024

Charters and Governing Documents

  • Board Charter
  • Audit and Risk Committee Charter
  • Remuneration and Nomination Committee Charter
  • Starpharma Constitution

Policy Documents

  • Anti-bribery and Corruption Policy
  • Environmental Policy
  • Code of Conduct Policy
  • Continuous Disclosure and Shareholder Communication Policy
  • Diversity Policy
  • Risk Management Policy
  • Securities Dealing Policy
  • Whistleblower Policy

Environment, Social and Governance (ESG)

  • Environment, Social and Governance Report 2024
  • Climate Change Position Statement

  • Investor Information
  • ASX Announcements
  • Financial Reports
  • Corporate Governance
  • News
  • Email Alerts
  • Annual General Meeting 2024

Discover More

ASX Announcements

ASX Announcements

ESG Commitments

ESG Commitments

Careers

Careers

Logo
  • 4-6 Southampton Crescent
    Abbotsford
    VICTORIA 3067
    AUSTRALIA
  • T: +61 3 8532 2700

Company

    • About Starpharma
    • Dendrimer Technology
    • DEP® Drug Delivery Platform
    • Leadership
    • Our Capabilities
    • Research Publications
    • ESG

Pipeline & Products

    • DEP® Pipeline
    • DEP® SN38
    • DEP® cabazitaxel
    • DEP® docetaxel
    • DEP® radiopharmaceuticals
    • DEP® antibody-drug conjugates
    • Anti-infective Products

Investors

    • Investor Information
    • ASX Announcements
    • Financial Reports
    • Corporate Governance
    • News
    • Email Alerts
    • Annual General Meeting 2024

People & Culture

    • Our People & Culture
    • Careers

Subscribe to Email Alerts

  • Disclaimer
  • Privacy
  • Search
© Starpharma Holdings Limited 2025 | This website is intended for people seeking information on Starpharma’s business.
We respectfully acknowledge the Wurundjeri Woi Wurrung People of the Kulin Nation, who are the Traditional Owners of the land on which Starpharma is based and we pay our respects to them and their country, and to Elders past and present.
Change your cookie preferences
Home
Company
About Starpharma
Dendrimer Technology
DEP® Drug Delivery Platform
Leadership
Our Capabilities
Research Publications
ESG
Home
Pipeline & Products
DEP® Pipeline
DEP® SN38
DEP® cabazitaxel
DEP® docetaxel
DEP® radiopharmaceuticals
DEP® antibody-drug conjugates
Anti-infective Products
Partnerships
Partnerships
Investors
Investor Information
ASX Announcements
Financial Reports
Corporate Governance
News
Email Alerts
Annual General Meeting 2024
People & Culture
Our People & Culture
Careers

You are now leaving the Starpharma website

You have selected a link that will redirect you to a site maintained by a third party who is solely responsible for its contents.

Starpharma provides this link as a service to website visitors. Starpharma is not responsible for the privacy policy of any third party websites. Read the privacy policy of every website you visit.

To proceed, click ‘continue’.

Continue